Zhang GL, Chen ZH. Correction to “Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome”. World J Diabetes 2026; 17(9): 124151 [DOI: 10.4239/wjd.124151]
Corresponding Author of This Article
Zhen-Huan Chen, Department of Cardiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Aiguo Road, Donghu District, Nanchang 330000, Jiangxi Province, China. chenzhenhuan@ncmc.edu.cn
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
correction
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zhang GL, Chen ZH. Correction to “Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome”. World J Diabetes 2026; 17(9): 124151 [DOI: 10.4239/wjd.124151]
World J Diabetes. Sep 15, 2026; 17(9): 124151 Published online Sep 15, 2026. doi: 10.4239/wjd.124151
Correction to “Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome”
Gu-Lao Zhang, Zhen-Huan Chen
Gu-Lao Zhang, Zhen-Huan Chen, Department of Cardiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang 330000, Jiangxi Province, China
Author contributions: Zhang GL identified the error in the original figure; Chen ZH reanalyzed the data and made corrections. All the authors have read and approved the final corrected text.
AI contribution statement: No AI tools was used as assistive technologies in this study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Zhen-Huan Chen, Department of Cardiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Aiguo Road, Donghu District, Nanchang 330000, Jiangxi Province, China. chenzhenhuan@ncmc.edu.cn
Received: June 9, 2026 Revised: June 22, 2026 Accepted: August 14, 2026 Published online: September 15, 2026 Processing time: 84 Days and 8.5 Hours
Abstract
Correction to “Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J Diabetes 2024; 15: 724-734 [PMID: 38680706 DOI: 10.4239/wjd.v15.i4.724]”. In the original publication, the bands of p-AMPK and AMPK in Figure 8A were placed wrongly. This error has now been corrected. In addition, the statistical symbol for the last group on the graph on the right side of Figure 8A has been corrected to “c”; “&” was incorrect.
Core Tip: In the original publication, the bands of p-AMPK and AMPK in Figure 8A were placed wrongly. This error has now been corrected. In addition, the statistical symbol for the last group on the graph on the right side of Figure 8A has been corrected to “c”; “&” was incorrect. We apologize for these errors and any confusion that they may have caused.
